Arbutus Biopharma Q2 Revenue Misses as HBV Drug Imdusiran Advances Toward Phase 2 Data

The Quick Take

• Arbutus Biopharma (ABUS) reported Q2 revenue below estimates amid ongoing patent litigation over its lipid nanoparticle delivery technology that underpins Moderna and Pfizer-BioNTech COVID-19 vaccines
• Pipeline asset imdusiran — an RNAi therapy targeting hepatitis B functional cure — remains the primary clinical catalyst with Phase 2 combination data expected within the next 12-18 months
• Patent litigation outcomes against major pharmaceutical companies represent binary upside for Arbutus shareholders independent of the HBV clinical development timeline

Arbutus Biopharma's Q2 revenue miss is characteristic of the pre-commercialisation biotech profile: current revenues derive primarily from royalties on its lipid nanoparticle intellectual property and litigation settlements, while the company awaits catalyst events from imdusiran, its lead hepatitis B programme. The Vancouver-based company's LNP technology — originally developed for RNA delivery — gained unexpected significance as the delivery mechanism for Moderna and Pfizer-BioNTech's mRNA COVID-19 vaccines, leading to royalty disputes now being adjudicated in concurrent patent proceedings. The outcome of these proceedings represents binary upside for shareholders alongside the clinical development catalyst.

Imdusiran's clinical programme targets hepatitis B functional cure — a therapeutic milestone no approved therapy has yet achieved and that would unlock a treatment segment covering approximately 290 million chronically infected patients globally. Phase 2 combination therapy data with existing antivirals and immune modulators expected in 2026 will determine whether the asset merits Phase 3 investment. For investors, the calculus is bifurcated: near-term patent litigation resolution providing cash inflows versus longer-term clinical success transforming Arbutus into a commercial-stage hepatitis B franchise with durable royalty-plus-product revenues.

The patent litigation trajectory is the most proximate catalyst for Arbutus, with court proceedings against Moderna and others regarding LNP patent ownership expected to yield rulings or settlement discussions within the next 18 months. A favourable ruling or substantial settlement would dramatically improve the company's financial position and extend its clinical runway materially. The macro variable: FDA accelerated approval pathways for viral cure programmes could shorten imdusiran's regulatory timeline if Phase 2 data supports recognised surrogate endpoints — a regulatory dynamics to monitor given the FDA's increasing receptivity to functional cure definitions across hepatitis B development programmes entering pivotal stages.

Synthesized from 1 source — full coverage, sentiment breakdown, and forward signals below.